Superluminal Medicines Secures $120 Million Series A Round for Clinical Development and Expansion of Small Molecule Pipeline
Superluminal Medicines Secures $120 Million Series A Round for Clinical Development and Expansion of Small Molecule Pipeline
09/09/24, 11:12 AM
Location
walthamMoney
$120 million
Industry
biotechnology
Type
partnership
Superluminal Medicines, Inc. has announced the closing of a $120 million Series A funding round led by RA Capital Management, with participation from existing investors and new investors such as Catalio Capital Management, Eli Lilly and Company, and Cooley LLP. The funds will support the progression of Superluminal’s lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets.
Company Info
Location
waltham, massachusetts, united states
Additional Info
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.